Inhibikase Therapeutics IKT
NASDAQ IKT
$2.50 -0.02 (-0.79%)
As of: Sep 4, 2026 · 3:59 PM EDT

Inhibikase Therapeutics (IKT) Price to Earnings (2020 - 2026)

Analysis

Inhibikase Therapeutics (IKT) Price to Earnings (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Inhibikase Therapeutics 435.56 Mn 276.54 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -16.83
Mar 31, 2026 -16.22
Dec 31, 2025 -14.63
Sep 30, 2025 -9.49
Jun 30, 2025 -13.41
Mar 31, 2025 -11.15
Dec 31, 2024 -5.96
Sep 30, 2024 -1.67
Jun 30, 2024 -1.73
Mar 31, 2024 -2.93
Dec 31, 2023 -1.78
Sep 30, 2023 -1.56
Jun 30, 2023 -3.08
Mar 31, 2023 -4.33
Dec 31, 2022 -2.91
Sep 30, 2022 -5.11
Jun 30, 2022 -4.04
Mar 31, 2022 -8.05
Dec 31, 2021 -5.31
Sep 30, 2021 -10.69